Cargando…

P2X7 in Cancer: From Molecular Mechanisms to Therapeutics

P2X7 is a transmembrane receptor expressed in multiple cell types including neurons, dendritic cells, macrophages, monocytes, B and T cells where it can drive a wide range of physiological responses from pain transduction to immune response. Upon activation by its main ligand, extracellular ATP, P2X...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lara, Romain, Adinolfi, Elena, Harwood, Catherine A., Philpott, Mike, Barden, Julian A., Di Virgilio, Francesco, McNulty, Shaun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287489/ https://www.ncbi.nlm.nih.gov/pubmed/32581786 http://dx.doi.org/10.3389/fphar.2020.00793

Ejemplares similares

The P2X7 Receptor 489C>T Gain of Function Polymorphism Favors HHV-6A Infection and Associates With Female Idiopathic Infertility
por: Pegoraro, Anna, et al.
Publicado: (2020)

The P2X7 Receptor-Interleukin-1 Liaison
por: Giuliani, Anna Lisa, et al.
Publicado: (2017)

Non-nucleotide Agonists Triggering P2X7 Receptor Activation and Pore Formation
por: Di Virgilio, Francesco, et al.
Publicado: (2018)

P2X7 Receptor Expression in Patients With Serositis Related to Systemic Lupus Erythematosus
por: Furini, Federica, et al.
Publicado: (2019)

P2X(7) receptor: Death or life?
por: Adinolfi, Elena, et al.
Publicado: (2005)

Editorial: Ion Channel Signalling in Cancer: From Molecular Mechanisms to Therapeutics
por: Jiang, Lin-Hua, et al.
Publicado: (2021)

ATP in the tumour microenvironment drives expression of nfP2X(7), a key mediator of cancer cell survival
por: Gilbert, SM, et al.
Publicado: (2018)

Differential sensitivity of acute myeloid leukemia cells to daunorubicin depends on P2X7A versus P2X7B receptor expression
por: Pegoraro, Anna, et al.
Publicado: (2020)

A2A Receptor Contributes to Tumor Progression in P2X7 Null Mice
por: De Marchi, Elena, et al.
Publicado: (2022)

Editorial: Emerging Mechanisms in Purinergic Signaling: From Cell Biology to Therapeutic Perspectives
por: Gomez-Villafuertes, Rosa, et al.
Publicado: (2020)

The P2X7 receptor is a key modulator of aerobic glycolysis
por: Amoroso, F, et al.
Publicado: (2012)

Duality of P2X7 Receptor in Amyotrophic Lateral Sclerosis
por: Volonté, Cinzia, et al.
Publicado: (2020)

The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment
por: De Marchi, Elena, et al.
Publicado: (2019)

Trophic Activity of Human P2X7 Receptor Isoforms A and B in Osteosarcoma
por: Giuliani, Anna Lisa, et al.
Publicado: (2014)

Searching Novel Therapeutic Targets for Scleroderma: P2X7-Receptor Is Up-regulated and Promotes a Fibrogenic Phenotype in Systemic Sclerosis Fibroblasts
por: Gentile, Daniela, et al.
Publicado: (2017)

Interaction of Purinergic P2X4 and P2X7 Receptor Subunits
por: Schneider, Markus, et al.
Publicado: (2017)

P2X7 is a cytotoxic receptor….maybe not: implications for cancer
por: Di Virgilio, Francesco
Publicado: (2020)

Amyloid β-dependent mitochondrial toxicity in mouse microglia requires P2X7 receptor expression and is prevented by nimodipine
por: Chiozzi, Paola, et al.
Publicado: (2019)

Blockade of Pannexin-1 Channels and Purinergic P2X7 Receptors Shows Protective Effects Against Cytokines-Induced Colitis of Human Colonic Mucosa
por: Diezmos, Erica F., et al.
Publicado: (2018)

Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases
por: Li, Chao, et al.
Publicado: (2020)

Non-aromatizable androgens modulate the lipopolysaccharide induced expression of the P2X7 receptor in human adipocytes
por: Di Vincenzo, Angelo, et al.
Publicado: (2023)

Ectonucleotidases in Acute and Chronic Inflammation
por: Giuliani, Anna Lisa, et al.
Publicado: (2021)

The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?
por: Savio, Luiz E. B., et al.
Publicado: (2018)

P2X7 Receptor–Mediated Inflammation in Cardiovascular Disease
por: Zhou, Junteng, et al.
Publicado: (2021)

P2X7 Variants in Oncogenesis
por: Pegoraro, Anna, et al.
Publicado: (2021)

P2X7 Receptor Blockade Protects Against Acrolein-Induced Bladder Damage: A Potential New Therapeutic Approach for the Treatment of Bladder Inflammatory Diseases
por: Taidi, Zhinoos, et al.
Publicado: (2021)

P2X7 Purinoceptor Affects Ectopic Calcification of Dystrophic Muscles
por: Rumney, Robin M. H., et al.
Publicado: (2022)

Insights into the Molecular Mechanisms Underlying Mammalian P2X7 Receptor Functions and Contributions in Diseases, Revealed by Structural Modeling and Single Nucleotide Polymorphisms
por: Jiang, Lin-Hua, et al.
Publicado: (2013)

P2X7 promotes metastatic spreading and triggers release of miRNA-containing exosomes and microvesicles from melanoma cells
por: Pegoraro, Anna, et al.
Publicado: (2021)

P2X7 Receptor in Hematological Malignancies
por: De Marchi, Elena, et al.
Publicado: (2021)

Alleviation of hippocampal necroptosis and neuroinflammation by NecroX-7 treatment after acute seizures
por: Roh, Yihyun, et al.
Publicado: (2023)

HIV drug nucleoside reverse transcriptase inhibitors as promising anti-inflammation therapeutics by targeting P2X7-dependent large pore formation: one stone for two birds?
por: Jiang, Lin-Hua
Publicado: (2015)

P2X3 Receptor Ligands: Structural Features and Potential Therapeutic Applications
por: Spinaci, Andrea, et al.
Publicado: (2021)

Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer
por: Zhou, Mengjiao, et al.
Publicado: (2022)

Irradiation causes senescence, ATP release, and P2X7 receptor isoform switch in glioblastoma
por: Zanoni, Michele, et al.
Publicado: (2022)

Recent Advances in CNS P2X7 Physiology and Pharmacology: Focus on Neuropsychiatric Disorders
por: Bhattacharya, Anindya
Publicado: (2018)

Purinergic P2X7 receptor antagonist ameliorates intestinal inflammation in postoperative ileus
por: KIMURA, Hitomi, et al.
Publicado: (2022)

Multifaceted Roles of Chemokine C-X-C Motif Ligand 7 in Inflammatory Diseases and Cancer
por: Wu, Qianmiao, et al.
Publicado: (2022)

FBXW7 and human tumors: mechanisms of drug resistance and potential therapeutic strategies
por: Wang, Wanqing, et al.
Publicado: (2023)

Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD
por: Zhu, Yanlin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_adpuuq66itnvg9kc2cg4rfamcu